7 completed. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 4 | Completed 4 |
Follow Accenture: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-finding Study in Platinum-Resistant Ovarian Cancer GSK2110183 in combination with carboplatin and paclitaxel - Recurrent Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Completed | Accenture | 59 | 2012-11-01 | 2018-04-02 |
| A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV) Ondansetron, Vestipitant - Postoperative Nausea and Vomiting | Phase 2 | Completed | Accenture | 131 | 2012-02-01 | 2012-10-02 |
| Single Dose Study of GSK1440115 in Patients With Asthma 1440115, Placebo - Asthma | Phase 1 | Completed | Accenture | 12 | 2011-08-01 | 2011-12-02 |
| Single Dose Safety Study for Compound to Treat Post-Operative Nausea and Vomiting (PONV) GW597599, Placebo - Post-Operative Nausea and Vomiting (PONV) | Phase 1 | Completed | Accenture | 55 | 2011-05-01 | 2011-10-13 |
| Repeat Dose Safety Study for Compound to Treat Asthma 1440115, Placebo - Asthma | Phase 1 | Completed | Accenture | 2010-09-01 | 2011-01-31 | |
| Dose Response Study of Patients With Erythematous Rosacea V-101, vehicle - Erythematous (Type One) Rosacea | Phase 2 | Completed | Vicept Therapeutics, Inc. | 175 | 2010-08-01 | 2010-11-24 |
| Repeat Dose Safety Study for Compound to Treat Hematologic Cancer GSK21110183 - Hematologic Malignancies | Phase 1 / Phase 2 | Completed | Accenture | 73 | 2009-07-01 | 2012-04-04 |
Asthma (2) · Erythema (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Multiple Myeloma (1) · Neoplasms (1) · Postoperative Nausea and Vomiting (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Rosacea (1) · Vomiting (1)
4'-(1-(((6,7-dichloro-3- oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-biphenylcarboxylic acid (2) · vestipitant (2) · Carboplatin (1) · GSK2110183 (1) · Ondansetron (1) · Paclitaxel (1)
Australia (5) · United States (2) · Canada (1) · Russia (1) · South Korea (1) · United Kingdom (1)
Andrew Dean (1) · Anne L Hamilton (1) · Bhawana Awasthy, MD (1) · Daniel M Stewart, DO (1) · Eduardo Tschen, MD (1) · Joseph F Fowler, MD (1) · Leslie S Baumann, MD (1) · Linda Mileshkin (1) · Marcia Hall (1) · Michael T Jarratt, MD (1) · Richard A Brigandi, MD, PhD (1) · Richard A Brigandi, MD, PhD, FAAP (1) · Robert T Matheson, MD (1) · S. Jamie Freedman, MD, PhD (1) · Sarah P Blagden (1)